| Dr Michael T Thieken, MD | |
|
10995 Allisonville Rd, #102, Fishers, IN 46038-2617 | |
| (317) 915-8110 | |
| (317) 915-8120 |
| Full Name | Dr Michael T Thieken |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 22 Years |
| Location | 10995 Allisonville Rd, Fishers, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063551588 | NPI | - | NPPES |
| 200915830 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 01058064A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana Orthopaedic Hospital, Llc | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopaedics-indianapolis Inc | 7416860663 | 169 |
News Archive
Exercise helps to keep the surrounding muscles strong to protect the joint, and also reduces stiffness that people frequently experience in the morning or after periods of inactivity. Joints are meant to move, so keeping them mobile will assist with joint health, maintain range of movement and enhance stability.
In May 2009, Riverview Medical Center became part of a research study sponsored by Johns Hopkins University called the Atlantic C-PORT-E Elective Angioplasty trial. Riverview was selected to participate in this research study for its high level of experience and outstanding cardiovascular services.
XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.
In a recent medRxiv* preprint paper, researchers from the University of Connecticut Health Center in the United States unveil their digital warm-start CRISPR (WS-CRISPR) method for stringent and sensitive quantitative detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples of patients with coronavirus disease (COVID-19).
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
› Verified 8 days ago
| Entity Name | Orthopaedics-indianapolis Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336252451 PECOS PAC ID: 7416860663 Enrollment ID: O20031124000328 |
News Archive
Exercise helps to keep the surrounding muscles strong to protect the joint, and also reduces stiffness that people frequently experience in the morning or after periods of inactivity. Joints are meant to move, so keeping them mobile will assist with joint health, maintain range of movement and enhance stability.
In May 2009, Riverview Medical Center became part of a research study sponsored by Johns Hopkins University called the Atlantic C-PORT-E Elective Angioplasty trial. Riverview was selected to participate in this research study for its high level of experience and outstanding cardiovascular services.
XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.
In a recent medRxiv* preprint paper, researchers from the University of Connecticut Health Center in the United States unveil their digital warm-start CRISPR (WS-CRISPR) method for stringent and sensitive quantitative detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples of patients with coronavirus disease (COVID-19).
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael T Thieken, MD 8450 Northwest Blvd, Indianapolis, IN 46278-1381 Ph: (317) 802-2000 | Dr Michael T Thieken, MD 10995 Allisonville Rd, #102, Fishers, IN 46038-2617 Ph: (317) 915-8110 |
News Archive
Exercise helps to keep the surrounding muscles strong to protect the joint, and also reduces stiffness that people frequently experience in the morning or after periods of inactivity. Joints are meant to move, so keeping them mobile will assist with joint health, maintain range of movement and enhance stability.
In May 2009, Riverview Medical Center became part of a research study sponsored by Johns Hopkins University called the Atlantic C-PORT-E Elective Angioplasty trial. Riverview was selected to participate in this research study for its high level of experience and outstanding cardiovascular services.
XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.
In a recent medRxiv* preprint paper, researchers from the University of Connecticut Health Center in the United States unveil their digital warm-start CRISPR (WS-CRISPR) method for stringent and sensitive quantitative detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples of patients with coronavirus disease (COVID-19).
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
› Verified 8 days ago
Kevin A Sonn, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 13100 E 136th St Ste 2000, Fishers, IN 46037 Phone: 317-962-4940 | |
Matthieu Zingg, Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 13000 E 136th St, Fishers, IN 46037 Phone: 804-356-6205 | |
Stephen B Sexson, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7436 Glenvista Pl, Fishers, IN 46038 Phone: 317-845-0889 | |
Dr. Erica Elizabeth Fisk, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 10995 Allisonville Rd Ste 102, Fishers, IN 46038 Phone: 317-915-8110 Fax: 317-915-8120 | |
Leonard T Buller, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 13100 E 136th St Ste 2000, Fishers, IN 46037 Phone: 317-688-5980 Fax: 317-566-2736 | |
Dr. Marc Stuart Zipper, D.O. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 13521 Promise Rd, Fishers, IN 46038 Phone: 317-770-9898 |